{"id":"ea4bcd7b-80d6-535a-8535-448edbac4d02","stable_key":"1fb6218a-60d1-55ea-87fe-07d15d0fc46f:atorvastatin-lowers-plasma-coenzyme-q10","predicate":"reduces","statement":"Atorvastatin 20 mg reduced plasma coenzyme Q10 by 26.1 percent, while pitavastatin 4 mg did not, despite comparable reductions in cholesterol.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"ee74e78d-4369-5ecf-be5b-c4a9956d0fdd","mechanism_event_label":"Atorvastatin 20 mg reduced plasma coenzyme Q10 by 26.1 percent, while pitavastatin 4 mg did not, despite comparable reductions in cholesterol.","subject":{"id":"64f4b2c7-afdf-5b9a-b6f9-015a7aa96eee","slug":"atorvastatin","display_name":"Atorvastatin","entity_type_key":"small_molecule"},"object":{"id":"9c47a458-6bce-5886-bbd3-dfe38a7ec6e9","slug":"coq-plasma-concentration","display_name":"Plasma coenzyme Q10 concentration","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"ee74e78d-4369-5ecf-be5b-c4a9956d0fdd","stable_key":"1fb6218a-60d1-55ea-87fe-07d15d0fc46f:atorvastatin-lowers-plasma-coenzyme-q10-event","event_type":"observed_relationship","label":"Atorvastatin 20 mg reduced plasma coenzyme Q10 by 26.1 percent, while pitavastatin 4 mg did not, despite comparable reductions in cholesterol.","description":"Atorvastatin 20 mg reduced plasma coenzyme Q10 by 26.1 percent, while pitavastatin 4 mg did not, despite comparable reductions in cholesterol.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"64f4b2c7-afdf-5b9a-b6f9-015a7aa96eee","slug":"atorvastatin","display_name":"Atorvastatin","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"9c47a458-6bce-5886-bbd3-dfe38a7ec6e9","slug":"coq-plasma-concentration","display_name":"Plasma coenzyme Q10 concentration","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"fb764579-6fd3-51ed-acbc-cfe09e01d2b4","slug":"pitavastatin","display_name":"Pitavastatin","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"duration","value_text":"Crossover phases, length not stated here","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"19 Japanese patients with heterozygous familial hypercholesterolaemia","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Atorvastatin 20 mg or pitavastatin 4 mg, open randomised four-phase crossover","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Pitavastatin lowered coenzyme Q10 by 7.7 percent without reaching significance, so this is a difference in degree; no adverse events or liver or muscle enzyme abnormalities were observed with either statin, and the authors state it remains to be seen whether the change relates to long-term safety.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"organism","value_text":"19 Japanese patients with heterozygous familial hypercholesterolaemia","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Atorvastatin 20 mg reduced plasma coenzyme Q10 by 26.1 percent, while pitavastatin 4 mg did not, despite comparable reductions in cholesterol.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia. (2008). https://pubmed.ncbi.nlm.nih.gov/17957184/ DOI: 10.1038/sj.clpt.6100396","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"Oral","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Plasma coenzyme Q10","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"97ba60ae-7691-545b-80c2-cbe5be4d8ded","evidence_kind":"source_excerpt","locator":"Lines 166-175","start_line":166,"end_line":175,"excerpt":"## atorvastatin-lowers-plasma-coenzyme-q10\nAtorvastatin 20 mg reduced plasma coenzyme Q10 by 26.1 percent, while pitavastatin 4 mg did not, despite comparable reductions in cholesterol.\nModel/species: 19 Japanese patients with heterozygous familial hypercholesterolaemia\nTissue/system: Plasma coenzyme Q10\nExposure: Atorvastatin 20 mg or pitavastatin 4 mg, open randomised four-phase crossover\nRoute: Oral\nDuration: Crossover phases, length not stated here\nLimits: Pitavastatin lowered coenzyme Q10 by 7.7 percent without reaching significance, so this is a difference in degree; no adverse events or liver or muscle enzyme abnormalities were observed with either statin, and the authors state it remains to be seen whether the change relates to long-term safety.\nPrimary reference: Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia. (2008). https://pubmed.ncbi.nlm.nih.gov/17957184/ DOI: 10.1038/sj.clpt.6100396\nAccess: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","model_system":"","directness":"reported_statement","verification_status":"source_derived_draft","notes":"","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"a4431d8c-34d7-5db7-9edf-a35f68feba39","stable_key":"import-1fb6218a-60d1-55ea-87fe-07d15d0fc46f","title":"Atorvastatin: mechanism of action from target occupancy to isoprenoids, transport, muscle and metabolism (2026-09-22)","document_type":"imported_text","citation_label":"Original AI-assisted curation of twelve primary studies resolved by PubMed title search and cross-checked against live PubMed metadata. Findings obtained with mevastatin, simvastatin or the statin class are recorded against those subjects. Study-specific citations, doses, negative findings and limitations retained. Not publisher full text.","file_path":"","sha256":"6307f1acf99f90662320328974781ee660348754257b1e1555701ad597edc8e5","revision_id":"447c5978-ba3f-58fe-ac85-664caa72e01b","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}